TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma-Reference-Cited by-同舟云学术

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

Published:2019-05-20 Issue:8 Volume:9 Page:1064-1079
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Goyal Lipika,Shi Lei,Liu Leah Y.,Fece de la Cruz Ferran^ORCID,Lennerz Jochen K.^ORCID,Raghavan Srivatsan,Leschiner Ignaty,Elagina Liudmila,Siravegna Giulia,Ng Raymond W.S.^ORCID,Vu Phuong,Patra Krushna C.,Saha Supriya K.,Uppot Raul N.,Arellano Ron,Reyes Stephanie,Sagara Takeshi,Otsuki Sachie,Nadres Brandon^ORCID,Shahzade Heather A.,Dey-Guha Ipsita,Fetter Isobel J.,Baiev Islam,Van Seventer Emily E.,Murphy Janet E.,Ferrone Cristina R.,Tanabe Kenneth K.,Deshpande Vikram,Harding James J.,Yaeger Rona,Kelley Robin K.,Bardelli Alberto,Iafrate A. John,Hahn William C.,Benes Cyril H.^ORCID,Ting David T.^ORCID,Hirai Hiroshi,Getz Gad^ORCID,Juric Dejan,Zhu Andrew X.,Corcoran Ryan B.,Bardeesy Nabeel

Funder

DOD | Congressionally Directed Medical Research ProgramsDOD | Congressionally Directed Medical Research Programs (CDMRP)

HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI)

V Foundation for Cancer ResearchV Foundation for Cancer Research (V Foundation)

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 248 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. m6A demethylase ALKBH5 maintains stemness of intrahepatic cholangiocarcinoma by sustaining BUB1B expression and cell proliferation;Translational Oncology;2024-03

2. Molecular pathology for cholangiocarcinoma: a review of actionable genetic targets and their relevance to adjuvant & neoadjuvant therapy, staging, follow-up, and determination of minimal residual disease;Hepatobiliary Surgery and Nutrition;2024-02

3. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer;Current Medicinal Chemistry;2024-02

4. Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2;Proceedings of the National Academy of Sciences;2024-02

5. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma;Journal of Hepatology;2024-02